Selected HKEX Announcements | Q Technology's camera module sales in May rose by approximately 40% year-on-year; Longfor Group's sales exceeded RMB 13.6 billion year-to-date

① Q Technology reported a year-over-year increase of approximately 40% in mobile camera module sales for May; what are the highlights in its other business segments? ② Longfor Group achieved over RMB 13.6 billion in contracted sales year-to-date; how did it perform in May alone?

cls.cnJun 9 20:28

Mabpharm-B (02181): The National Medical Products Administration has approved the marketing authorization application for pipeline product CMAB807 Prolia (denosumab injection).

Mabion-B (02181) announced that the new drug application (NDA) for its pipeline product CMAB807 Prolia (denosumab injection) has recently been approved by the National Medical Products Administration (NMPA) of the People's Republic of China for the treatment of: (i) osteoporosis in postmenopausal women at high risk of fracture, in whom the product significantly reduces the risk of vertebral, non-vertebral, and hip fractures; (ii) osteoporosis in men at high risk of fracture; and (iii) glucocorticoid-induced osteoporosis in patients at high risk of fracture.

Zhitong FinanceJun 9 18:33

As the ASCO annual meeting approaches, the number of LBA for domestically innovative drugs has reached a new high, with three key investment themes worth noting.

A total of 63 studies were selected as Late-Breaking Abstracts (LBA) at this year's ASCO, including 13 studies from 12 companies based in China; notable domestically developed innovative drugs selected for LBA include AK112 from Akeso Biopharma and sintilimab plus chemotherapy from Innovent Bio; Huatai Securities stated that China's innovative drug sector is rapidly emerging as a defining force in global oncology treatment paradigms, with first-line lung cancer being one of the key focuses at this year’s ASCO.

cls.cnMay 4 14:15

Mabpharm Sets 2026 AGM, Seeks 10% Share Buyback Mandate

TipRanksApr 27 17:21

MABPHARM-B: 2025 Annual Report

HKEXApr 27 16:30 · Announcements

Trump takes action on pharmaceuticals! Import drugs face a maximum tax rate of 100%.

Trump fulfilled his threat by imposing a tariff of up to 100% on certain imported patented drugs. However, giants such as Merck and Eli Lilly and Co had already privately 'negotiated for exemptions.' Who will ultimately bear the brunt?

Golden10 DataApr 3 07:59